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Abstract
Purpose To determine whether Activin A affects the activa-
tion and survival of human primordial follicles in vitro.
Methods Ovarian cortical biopsies from eight women under-
going elective caesarean sections or benign gynaecological
procedures were taken and cut into small pieces (1–3 mm3),
cultured in serum-free medium for 7 days with/without
human recombinant Activin A at a concentration of either 50
or 100 ng/ml. Ovarian tissue were analysed by histology for
follicle viability, development and density.
Result(s) Significant activation of primordial follicles within
cultured cortical tissue was observed after 7 days in control
medium. However, medium supplemented with Activin A at
50 ng/ml resulted in significant inhibition of follicular
activation. Increasing the concentration of Activin A to
100 ng/ml reversed the inhibitory effect. The effect of Activin
A appeared to be specific to activation of non-growing
(primordial) follicles into the growing population since no
significant differences in follicle viability was observed
between treatment groups.
Conclusion(s) Activin A at a concentration of 50 ng/ml can
inhibit the spontaneous activation of human primordial
follicles in vitro indicating that this may be a component of
the signalling mechanisms that maintain follicular quiescence.
Keywords Primordial follicle . Activin A . In vitro culture .
Ovarian cortical tissue
Introduction
It is estimated that one in 715 of the adult population has
been treated for cancer in childhood [1, 2]. Advances in
treatments now highlight the adverse affects of such
medicines on female fertility. Chemotherapy regimens vary
in their gonadotoxicity [3] but for many young women
premature ovarian failure (POF) is a likely outcome. To
preserve their fertility options many women are now able to
store ovarian cortical tissue prior to treatment. However, the
option to use this tissue is currently limited to transplanta-
tion that may not be suitable for all women [4]. There is
therefore a pressing demand for improvement in the area of
female fertility preservation and this underpins the drive to
develop techniques to support oocyte growth from the
abundant population of primordial follicles to maturity in
vitro [5]. Such culture systems have been developed for
mice and offspring have been produced from oocytes
developed in vitro from primordial follicles [6, 7]. Similar
culture systems have been difficult to develop in humans
but the feasibility of this approach has been demonstrated
by the development of human antral follicles from
Capsule This study observed a dose dependent inhibitory action of
Activin A on the activation of human primordial follicles in vitro.
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primordial / primary stages using a two-step culture system
[8]. To optimise these systems a greater understanding of
factors regulating early follicle development is required.
Maintenance of the “resting” primordial pool of follicles
appears mainly to be regulated by inhibitory factors [9] and
the removal of ovarian tissue from its in vivo environment
induces spontaneous activation and growth of primordial
follicles [8, 10–13]. This spontaneous activation may lead
to increased degeneration therefore it is important to
optimise culture conditions to support these early stages.
Previous work has shown that Activin A promotes growth
and improves health of human preantral follicles grown in
vitro and the aim of this study was to determine whether
Activin had a similar effect at primordial stages.
Activins, which belong to the superfamily of TGFβ, are
homodimers composed of two inhibin β subunits termed
βA and βB. Three isoforms of Activin exist, differing in
their β subunits (βAβA as Activin A, βBβB as Activin B
and βAβB as Activin AB). Activin A is the most abundant
isoform of activins and the most extensively studied
member of the TGFβ family. Activin is produced by
granulosa cells of the ovary and it has been localised in
granulosa cells from primary to tertiary follicles [14].
Similar to other TGFβ family members, Activin A
influences many facets of cell activities such as prolifera-
tion, differentiation, motility and apoptosis through the
transmembrane receptor mediated Smad pathway. It has
complex regulatory mechanisms modulated by extracellular
binding proteins (follistatin, β glycan), intracellular antag-
onistic I-Smads and post transcription modulators [15, 16].
Activin A has been demonstrated to promote granulosa cell
proliferation in a dose dependant manner [17, 18].
Studies into the role of Activin A in early folliculo-
genesis have produced conflicting results that appear to be
stage, age and dose dependent. While, Activin A is
generally believed to have a stimulatory role on the
preantral stage of follicular development [7, 8, 19–22],
there are studies that show its inhibitory role in follicular
growth and development at this stage [23, 24]. The aim of
this study was to determine whether Activin affected the
activation of primordial follicles in vitro and the subsequent
health of growing follicles.
Materials and methods
Patients
Ovarian cortical biopsies of approximately 5–10 mm2 were
collected after informed consent from 8 women aged 26–
39 years (mean ± SD=33±5 years) undergoing elective
caesarean sections (n=5) or benign gynaecological proce-
dures (n=3) at the Edinburgh Royal Infirmary. Written
consent was obtained from each patient, and the study was
approved by the local ethics committee.
Ovarian tissue culture
Tissue collected during the surgical procedure was transported
immediately to the laboratory on a gauze soaked in normal
saline (n=8). Under sterile conditions, the biopsy tissue was
cut into smaller pieces of 2 mm2 (range of 1–3 mm2). A piece
from each fresh biopsy sample was taken and fixed
immediately for histological analysis, whilst the remainder
were cultured in pre-warmed 24 well culture dishes (Nunclon,
Nunc, Denmark) with inserts (0.4 um Millicell Culture Plate
Inserts, Millipore, France) for 7 days. Three pieces of tissue
from each specimen were added to each well containing
200 ul of either control medium [McCoys 5A modified
medium supplemented with Human Serum Albumin
(5 mg/ml), Penicillin G/Streptomycin Sulphate (0.1 mg/ml),
CGMP (1.1 mg/ml), Fresh Ascorbic Acid (50 ug/ml),
L-Glutamine (3 mM), Transferrin (2.5 ug/ml), Selenium
(4 ng/ml), Insulin (10 ug/ml) and FSH (0.5 IU/ml), all Sigma
Chemicals Poole] with or without either 50 or 100 ng of
Activin A (Invitrogen) inside and outside of the insert in a
humidified incubator at 37°C with 5% CO2 in air. Every
second day 200 ul of culture medium within the inserts was
removed and replaced with fresh medium.
Fixation and histological analysis
Cultured tissue was removed after 7 days and fixed in
Bouin’s solution for 12 h then dehydrated in increasing
concentrations of ethanol (70%, 90% and 100%). Follow-
ing dehydration, tissue was immersed in cedar wood oil
(BDH Laboratory Supplies, Poole UK) for 24 h then placed
in toluene (Fisher Scientific UK Ltd, Loughborough UK)
for 30 min to remove all traces of the oil. Tissue was then
embedded in paraffin wax at 60°C for 4 h, the wax being
renewed every hour to ensure complete clearance of all the
toluene. 6 um thick sections were cut, mounted on gelatine
coated slides and left to dry overnight prior to staining with
haematoxylin and eosin.
A complete morphological analysis and follicle count was
carried out on every 10th section. Follicles were only counted
and photographed when the oocyte nucleolus was present to
avoid double counting. Developmental stages of viable
follicles were classified based on granulosa cell morphology
surrounding the follicle: (1) Primordial stage: oocyte sur-
rounded by a layer of flattened granulosa cells; (2) Primary
stage: oocyte surrounded by a complete layer of cuboidal
granulosa cells; (3) secondary stage: oocyte surrounded by
two or more layers of cuboidal granulosa cells. The proportion
of follicles at different developmental stage is defined as
percentage of viable follicle over the total count.
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Follicles were classified for viability using a previously
described method [8]: type 1: intact oocyte (regular shape
and even cytoplasm) in contact with a complete layer of
granulosa cells and less than 10% of pyknotic granulosa cells
present; type 2: misshapen oocyte still surrounded by
granulosa cells with more than 10% pyknotic granulosa
cells; type 3: oocyte dissociated from granulosa cells with
more than 10% pyknotic granulosa cells; type 4: fragmented
oocyte with more than 10% pyknotic granulosa cells. For
analytical purposes, results were then grouped into viable
follicle (including type 1 and 2 follicles) and nonviable
follicle (including type 3 and 4 follicles). Follicle viability or
proportion of viable follicles is defined as percentage of the
number of viable follicles out of the total scored.
The integrated measuring tool in the ImageJ software
(http://rsbweb.nih.gov/ij/) was used to measure tissue area
after calibration with a stage micrometer. The volume of a
tissue slide is computed by multiplying the tissue area with
the known thickness (6 um) of each section. The sum of the
volume of all slides for a tissue sample is therefore the
volume of the tissue. Follicle density of a tissue is defined
as the number of follicles divided by the tissue volume.
Statistical analysis
Statistical comparisons between groups for all data (viabil-
ity, development and density) were carried out using t-test.
Before analysis, the percentage data were normalized using
arcsine transformation. Bonferroni’s correction was used to
correct for multiple testing. Significance is reported at the
0.017 level (0.05 before Bonferroni’s correction). Data are
presented as mean ± SEM.
Results
A total of 1137 follicles from eight patients were examined
under the light microscope. The numbers of follicles
obtained from each patient together with their age are
shown in Table 1.
71% of follicles in freshly isolated uncultured tissue (Fig. 1)
were identified as primordial. After 7 days of culture
significant activation of primordial follicles was observed
(73.7% growing) in the control medium, however tissue
cultured in medium supplemented with Activin A at 50 ng/ml
demonstrated significant inhibition of activation of the
primordial population compared with the control medium
[53.6% of follicles at primordial stage in presence of 50 ng/ml
Activin A compared with 26.3% in control medium (p<
0.003)] (Fig. 2). Tissue cultured at the higher dose of Activin
A (100 ng/ml) did not show this inhibitory effect after 7 days
in culture and the proportion of primordial follicles was not
significantly different from that in control media (31.6%).
The proportion of viable follicles after 7 days of culture
was significantly reduced by culturing but not affected by
treatment with Activin A (42.5% in control group, 41.1% in
50 ng/ml and 51.3% in 100 ng/ml Activin A) compared
with the fresh uncultured tissue at day 0 (92.9%) (P=0.001
between the uncultured tissue and all cultured groups, P>
0.313 between all cultured groups). (Fig. 3)
Patient A B C D E F G H Mean SEM Total
Age 34 36 29 38 30 34 39 26 33 0.57
Follicle No. 258 188 116 180 170 52 111 62 142 8.7 1137
Table 1 Display data on age
and the number of follicles
studied for each individual
patient
Fig. 1 Follicles photographed
under 400× magnification
using a light microscope
(a) Uncultured fresh ovarian
tissue with primordial follicles
(b) Primordial follicle after
7 days culture supplemented
with 50 ng/ml Activin A
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Whilst variation in follicle density was observed be-
tween patients, no significant differences were observed
between any of the treatment groups either before or after
culture (Fig. 4).
Qualitative assessment of the surrounding cellular compart-
ments of follicles indicates there may be a correlation between
the inhibition of follicles and increased stromal cell density
(Fig. 5). The most dense stroma was found in fresh uncultured
tissue followed by tissue cultured with supplemented Activin
A (50 ng/ml similar to 100 ng/ml) and the least dense stroma
was found in the tissue cultured with control medium.
Discussion
Central to our understanding of female fertility and
developing in vitro growth systems is to know how the
“resting” population of primordial follicles is regulated.
Components of this regulation involve suppressive and
activating factors [25, 26]. This is the first study to examine
the role of Activin A in the activation of human primordial
follicles and we have found that Activin A has a dose
dependent inhibitory effect on this process. The proportion
of primordial follicles activated to grow was significantly
Fig. 2 Histogram showing the proportion of follicles at the primordial
(dark blue bars), primary (medium blue bars) and secondary (light blue
bars) stages of development in histological samples taken from human
ovarian cortical biopsies at the time of collection (Day 0-baseline) and
after 7 days of culture in mediums (control medium, medium
supplemented with 50 ng/ml or 100 ng/ml of Activin A) of different
treatment groups (n=8 for all group). Compared to uncultured Day 0 –
baseline, all cultured tissues, with the exception of medium supple-
mented with 50 ng/ml of Activin A, had significantly less primordial
follicles and more primary follicles. *P<0.01 versus Day 0 –baseline
group for the same follicle developmental stage, #P<0.01 versus Day
7- control group
Fig. 3 Histogram demonstrat-
ing the proportion of viable
follicles in Day 0 baseline –
uncultured fresh tissue and tis-
sue cultured in control medium
or medium supplemented with
50 ng/ml or 100 ng/ml Activin
A for 7 days (n=8 for all
groups). *P<0.001 versus Day 0
baseline uncultured group
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lower in the presence of 50 ng/ml of Activin A compared
with control or medium containing 100 ng/ml Activin A.
Activin A has been associated with a stimulatory role
during the growing stages of follicle development in a range
of species and we have previously shown that its presence
enhances in vitro growth of human preantral follicles [8].
However, inhibitory actions of Activin A on small secondary
murine follicles have been reported [23]. Indeed, inhibitory
roles of activin A have been documented in various cells and
tissues such as CHO-K1 (Chinese hamster ovary) cell line
[27], and more recently in the luteinisation of human
granulosa cells [28]. The exact mechanism of Activin A’s
inhibitory action is not known but there is some evidence in
mice that changes in intraovarian concentration of Activin
affects follicle development in a stage dependent manner
[23] and the data presented here agrees with that.
Activin ligands act as homodimers of ßA subunits
(activin A) or ßB subunits (activin B) binding transmem-
brane receptors, which signal through either Smad or
extracellular signal-regulated protein kinase (Erk) pathways
to affect cell function [29]. The subunits along with the
activin receptors type I, IIA and IIB are expressed in
ovarian cells during follicular development in human
ovaries [30]. Activin or activin receptors have not been
localised in human primordial or primary follicles but
activin type II receptor has been localised in human
secondary follicles [31]. Therefore the effect on primordial
follicle activation observed in this study may be the result
of an indirect effect of Activin acting via another cell type,
possibly stromal cells.
Little is known about the underlying signalling pathways
that affect primordial follicle activation but a growing
Fig. 4 Histogram displaying the
follicle density (mean ± SEM)
measured as the total number of
follicles per cubic millimetre
observed in all treatment groups
(n=8)
Fig. 5 Photographed cultured
human ovarian cortical tissue
demonstrating the differences in
stromal density found in tissue
cultured in control medium (a)
and Activin A (50 ng/ml) (b)
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body of evidence is now emerging to show that the
phosphatidylinositol-3′-kinase (PI3K-AKT) pathway is a
major regulator of early follicle/oocyte development and
that components of this pathway are involved in controlling
the rate of activation from the non-growing population of
follicles [32]. A recent study showed that the phosphatase
PTEN acts within the oocyte as a negative regulator of
PI3K-AKT and suppresses activation of follicle develop-
ment in mice [33]. Whether Activin signalling in this
culture model affects the PI3K pathway either directly or
indirectly should be investigated further.
The absence of an inhibitory effect on follicle activation
observed at the higher concentration of Activin A (100 ng/ml)
is in accordance with findings from other published animal
studies. Mouse ovaries cultured in the presence of 100 ng/ml
of Activin A showed no significant difference on the
activation of primordial follicles when compared to the control
group [34]. This higher dose of Activin-A may be stim-
ulating an increased production of follistatin therefore
reducing the biological activity of Activin or it could be
altering the differentiation of somatic cells and therefore
altering the downstream effect of activin signalling. Further
studies using our culture models will be required to elucidate
these actions.
It has been suggested that Activin A may inhibit
follicular development through atretogenic action. Intra-
bursal injection of Activin A has been reported to increase
the number of atretic follicles and decrease granulosa cell
proliferation [35]. The results presented here indicate that
the increased proportion of non-growing follicles observed
in 50 ng/ml Activin (54%) compared to control group
(26%) was not due to an increase in atresia since no dif-
ferences in total numbers or viability were detected between
groups suggesting that the reduction of the growing follicle
in Activin A (50 ng/ml) group is a result of growth inhi-
bition. Our result is in accordance with other reported
studies [23, 27, 34] demonstrating a neutral effect of
Activin A on follicle survival.
Conclusions
In summary, based on our results, we suggest Activin A
may play a role in inhibiting and controlling the recruitment
of primordial follicles and their early growth in humans.
The exact mechanism for the inhibitory action of Activin
still needs to be determined. This may involve studies into
the possible differential effects on the neighbouring stromal
cell compartment. Further studies to elucidate the revers-
ibility of this dose dependent effect may shed light on the
complex interplay/mechanism responsible for the fine
regulation of selection and the activation of growth of
primordial follicles from the dormant pool.
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